NCT02227277 (BEAT-HIV) is a Phase 2 clinical trial of Peg-IFN-α2b in HIV, sponsored by The Wistar Institute.

Who is sponsoring NCT02227277?

NCT02227277 is sponsored by The Wistar Institute.

What drugs are being tested in NCT02227277?

Interventions in NCT02227277: Peg-IFN-α2b.

What condition does NCT02227277 study?

NCT02227277 studies HIV, HIV/AIDS.

Is NCT02227277 still recruiting?

NCT02227277 is currently status unknown. Last updated 5 April 2018.

Last reviewed 2018-04-05 · How we verify

NCT02227277: BEAT-HIV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reducing Proviral HIV DNA With Interferon-a

Status unknown Phase 2 Last updated 5 April 2018

What this trial tests

Phase 2 trial testing Peg-IFN-α2b in HIV in 54 participants. Status unknown.

Timeline

11 February 2015

Primary endpoint
7 February 2018

24 July 2018

Quick facts

Lead sponsor	The Wistar Institute
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	11 February 2015
Primary completion	7 February 2018
Estimated completion	24 July 2018
Sites	3 locations across United States

Drugs / interventions tested

Peg-IFN-α2b

Conditions studied

HIV — all drugs for HIV →
HIV/AIDS — all drugs for HIV/AIDS →

Sponsor

The Wistar Institute

Who can join

Adults 18 to 65, any sex, with HIV or HIV/AIDS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if treatment with pegylated interferon alpha 2b (peg-IFN-α2b) will reduce the amount of integrated HIV DNA in peripheral blood cells and tissues of individuals with chronic HIV infection receiving antiretroviral treatment (ART). A reduction and/or clearance of the latent viral reservoir (i.e.: virus that remains dormant in HIV-infected subjects receiving suppressive treatment ) is considered essential for HIV eradication. By measuring the changes in integrated proviral HIV DNA, which is considered a surrogate measure of the latent reservoir, the investigators will establish if peg-IFN-α2b treatment should be considered as a component of future viral eradication strategies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for HIV

Currently open trials in the same condition.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting

Other The Wistar Institute trials

Trials by the same sponsor.

NCT01935089 — Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02227277 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Wistar Institute
Last refreshed: 5 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02227277.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing